Clinical CHD Therapy - Early Clinical Trial Unit


Funding ID

81Z1600514

Project number

439

Institution
Deutsches Herzzentrum München
Project leader
Adnan Kastrati
Site
München
Short description

The objective is 2 fold: evaluation of new therapeutic concepts for the prevention of stent thrombosis and restenosis. A new substance, a glycoproten VI inhibitor, Revacept, which … 

The objective is 2 fold: evaluation of new therapeutic concepts for the prevention of stent thrombosis and restenosis. A new substance, a glycoproten VI inhibitor, Revacept, which prevents the adhesion of platelets to the vessel wall injury site, is expected to protect against thrombosis without impacting significantly on bleeding. Preclinical and phase I studies have shown promise that Revacept might be an effective and safe drug for prevention of thrombotic events after percutaneous coronary intervention. This substance will be assessed in a phase II clinical trial. The second objective is the development of safer and effective drug-eluting stents. RGD peptide and novel fully resorbable polymers will be subject of pre-clinical and first-in-man studies. We are establishing an early clinical trial unit for the conductance of these studies.

Project type
Partner Site Projects
Keywords
Coronary artery disease, thrombosis, restenosis, platelet, aggregation, stent, women,antiproliferative drug, antiplatelet drug, clinical trial, phase II
Funding
€ 1.308.270,36
Begin
15.10.2011
End
31.12.2018